Chow LQM (2020) Head and neck cancer. N Engl J Med 382(1):60–72
Article CAS PubMed Google Scholar
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F (2021) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71(3):209–249
Alterio D, Marvaso G, Ferrari A, Volpe S, Orecchia R, Jereczek-Fossa BA (2019) Modern radiotherapy for head and neck cancer. Semin Oncol 46(3):233–245
Article CAS PubMed Google Scholar
Yang Z, Zhang X, Wang X, Zhu XR, Gunn B, Frank SJ, Chang Y, Li Q, Yang K, Wu G, Liao L, Li Y, Chen M, Li H (2020) Multiple-CT optimization: an adaptive optimization method to account for anatomical changes in intensity-modulated proton therapy for head and neck cancers. Radiother Oncol 142:124–132
Article CAS PubMed Google Scholar
Li CX, Sun JL, Gong ZC, Liu H, Ding MC, Zhao HR (2023) An umbrella review exploring the effect of radiotherapy for head and neck cancer patients on the frequency of jaws osteoradionecrosis. Cancer Radiother 27(5):434–446
Article CAS PubMed Google Scholar
Gensheimer MF, Le QT (2018) Adaptive radiotherapy for head and neck cancer: are we ready to put it into routine clinical practice? Oral Oncol 86:19–24
Spencer S (2018) Head and neck cancers: advantages of advanced radiation therapy and importance of supportive care. J Natl Compr Canc Netw 16(5S):666–669
Gorgoulis V, Adams PD, Alimonti A, Bennett DC, Bischof O, Bishop C, Campisi J, Collado M, Evangelou K, Ferbeyre G, Gil J, Hara E, Krizhanovsky V, Jurk D, Maier AB, Narita M, Niedernhofer L, Passos JF, Robbins PD et al (2019) Cellular senescence: defining a path forward. Cell 179(4):813–827
Article CAS PubMed Google Scholar
Caudell JJ, Torres-Roca JF, Gillies RJ, Enderling H, Kim S, Rishi A, Moros EG, Harrison LB (2017) The future of personalised radiotherapy for head and neck cancer. Lancet Oncol 18(5):e266–e273
Article PubMed PubMed Central Google Scholar
Marzec J, Marzec L, Martus P, Zips D, Müller AC (2018) MATLAB®-based fitting method to evaluate survival fractions after multimodal treatment. Clin Transl Radiat Oncol 10:36–41
PubMed PubMed Central Google Scholar
Widmark A, Gunnlaugsson A, Beckman L, Thellenberg-Karlsson C, Hoyer M, Lagerlund M, Kindblom J, Ginman C, Johansson B, Björnlinger K, Seke M, Agrup M, Fransson P, Tavelin B, Norman D, Zackrisson B, Anderson H, Kjellén E, Franzén L, Nilsson P (2019) Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial. Lancet 394(10196):385–395
Björk-Eriksson T, West C, Karlsson E, Mercke C (2000) Tumor radiosensitivity (SF2) is a prognostic factor for local control in head and neck cancers. Int J Radiat Oncol Biol Phys 46(1):13–19
Overgaard J, Mohanti BK, Begum N, Ali R, Agarwal JP, Kuddu M, Bhasker S, Tatsuzaki H, Grau C (2010) Five versus six fractions of radiotherapy per week for squamous-cell carcinoma of the head and neck (IAEA-ACC study): a randomised, multicentre trial. Lancet Oncol 11(6):553–560
Lazarev S, Gupta V, Ghiassi-Nejad Z, Miles B, Scarborough B, Misiukiewicz KJ, Reckson B, Sheu RD, Bakst RL (2017) Premature discontinuation of curative radiation therapy: insights from head and neck irradiation. Adv Radiat Oncol 3(1):62–69
Article PubMed PubMed Central Google Scholar
Pedicini P, Caivano R, Fiorentino A, Strigari L (2015) Clinical radiobiology of head and neck cancer: the hypothesis of stem cell activation. Clin Transl Oncol 17(6):469–476
Article CAS PubMed Google Scholar
Schoetz U, Klein D, Hess J, Shnayien S, Spoerl S, Orth M, Mutlu S, Hennel R, Sieber A, Ganswindt U, Luka B, Thomsen AR, Unger K, Jendrossek V, Zitzelsberger H, Blüthgen N, Belka C, Unkel S, Klinger B, Lauber K (2021) Early senescence and production of senescence-associated cytokines are major determinants of radioresistance in head-and-neck squamous cell carcinoma. Cell Death Dis 12(12):1162
Article CAS PubMed PubMed Central Google Scholar
Chaturvedi AK, Engels EA, Anderson WF, Gillison ML (2008) Incidence trends for human papillomavirus-related and -unrelated oral squamous cell carcinomas in the United States. J Clin Oncol 26(4):612–619
Ang KK, Harris J, Wheeler R, Weber R, Rosenthal DI, Nguyen-Tân PF, Westra WH, Chung CH, Jordan RC, Lu C, Kim H, Axelrod R, Silverman CC, Redmond KP, Gillison ML (2010) Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med 363(1):24–35
Article CAS PubMed PubMed Central Google Scholar
Browman GP, Mohide EA, Willan A, Hodson I, Wong G, Grimard L, MacKenzie RG, El-Sayed S, Dunn E, Farrell S (2002) Association between smoking during radiotherapy and prognosis in head and neck cancer: a follow-up study. Head Neck 24(12):1031–1037
Fortin A, Wang CS, Vigneault E (2009) Influence of smoking and alcohol drinking behaviors on treatment outcomes of patients with squamous cell carcinomas of the head and neck. Int J Radiat Oncol Biol Phys 74(4):1062–1069
Wun T, Law L, Harvey D, Sieracki B, Scudder SA, Ryu JK (2003) Increased incidence of symptomatic venous thrombosis in patients with cervical carcinoma treated with concurrent chemotherapy, radiation, and erythropoietin. Cancer 98(7):1514–1520
Article CAS PubMed Google Scholar
Tham T, Olson C, Wotman M, Teegala S, Khaymovich J, Coury J, Costantino P (2018) Evaluation of the prognostic utility of the hemoglobin-to-red cell distribution width ratio in head and neck cancer. Eur Arch Otorhinolaryngol 275(11):2869–2878
Li CX, He Q, Wang ZY, Fang C, Gong ZC, Zhao HR, Ling B (2023) Risk assessment of venous thromboembolism in head and neck cancer patients and its establishment of a prediction model. Head Neck 45(10):2515–2524
Clayburgh DR, Stott W, Cordiero T, Park R, Detwiller K, Buniel M, Flint P, Schindler J, Andersen P, Wax MK, Gross N (2013) Prospective study of venous thromboembolism in patients with head and neck cancer after surgery. JAMA Otolaryngol Head Neck Surg 139(11):1143–1150
Maahs L, Ghanem AI, Gutta R, Tang A, Arya S, Al Saheli Z, Ali H, Chang S, Tam S, Wu V, Siddiqui F, Sheqwara J (2022) Cetuximab and anemia prevention in head and neck cancer patients undergoing radiotherapy. BMC Cancer 22(1):626
Article CAS PubMed PubMed Central Google Scholar
Shenouda G, Zhang Q, Ang KK, Machtay M, Parliament MB, Hershock D, Suntharalingam M, Lin A, Rotman M, Nabid A, Hong S, Shehata S, Cmelak AJ, Sultanem K, Le QT (2015) Long-term results of radiation therapy oncology group 9903: a randomized phase 3 trial to assess the effect of erythropoietin on local-regional control in anemic patients treated with radiation therapy for squamous cell carcinoma of the head and neck. Int J Radiat Oncol Biol Phys 91(5):907–915
Article CAS PubMed PubMed Central Google Scholar
Talukdar S, Emdad L, Das SK, Fisher PB (2020) EGFR: an essential receptor tyrosine kinase-regulator of cancer stem cells. Adv Cancer Res 147:161–188
Article CAS PubMed Google Scholar
Fasano M, Della Corte CM, Viscardi G, Di Liello R, Paragliola F, Sparano F, Iacovino ML, Castrichino A, Doria F, Sica A, Morgillo F, Colella G, Tartaro G, Cappabianca S, Testa D, Motta G, Ciardiello F (2021) Head and neck cancer: the role of anti-EGFR agents in the era of immunotherapy. Ther Adv Med Oncol 13:1758835920949418
Article CAS PubMed PubMed Central Google Scholar
Kumar R, George B, Campbell MR, Verma N, Paul AM, Melo-Alvim C, Ribeiro L, Pillai MR, da Costa LM, Moasser MM (2020) HER family in cancer progression: from discovery to 2020 and beyond. Adv Cancer Res 147:109–160
Article CAS PubMed Google Scholar
Liu Q, Yu S, Zhao W, Qin S, Chu Q, Wu K (2018) EGFR-TKIs resistance via EGFR-independent signaling pathways. Mol Cancer 17(1):53
Article PubMed PubMed Central Google Scholar
Gröbe A, Eichhorn W, Fraederich M, Kluwe L, Vashist Y, Wikner J, Smeets R, Simon R, Sauter G, Heiland M, Blessmann M (2014) Immunohistochemical and FISH analysis of EGFR and its prognostic value in patients with oral squamous cell carcinoma. J Oral Pathol Med 43(3):205–210
Bonner JA, Harari PM, Giralt J, Cohen RB, Jones CU, Sur RK, Raben D, Baselga J, Spencer SA, Zhu J, Youssoufian H, Rowinsky EK, Ang KK (2010) Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol 11(1):21–28
Article CAS PubMed Google Scholar
Goldberg RM (2005) Cetuximab. Nat Rev Drug Discov S10–S11. https://doi.org/10.1038/nrd1728
Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB, Jones CU, Sur R, Raben D, Jassem J, Ove R, Kies MS, Baselga J, Youssoufian H, Amellal N, Rowinsky EK, Ang KK (2006) Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 354(6):567–578
Article CAS PubMed Google Scholar
Ang KK, Berkey BA, Tu X, Zhang HZ, Katz R, Hammond EH, Fu KK, Milas L (2002) Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. Cancer Res 62(24):7350–7356
Comments (0)